Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling

Affiliations

• ¹ PinneyAssociates, Inc, 4800 Montgomery Lane, Suite 400, Bethesda, MD, USA; Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: [email protected].
• ² PinneyAssociates, Inc, 4800 Montgomery Lane, Suite 400, Bethesda, MD, USA.
• ³ Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
• ⁴ Substance Abuse and Mental Health Services Administration, Rockville, MD, USA.
• ⁵ Chief of Pain and Palliative Care, Senior Research Clinician (Full Professor). National Institutes of Health Clinical Center, Bethesda, MD, USA.
• ⁶ MAPS Public Benefit Corporation (MAPS PBC), San Jose, CA, USA; Department of Neurology, University of California, San Francisco, CA, USA.
• ⁷ Columbia University, Irving Medical Center, New York State Psychiatric Institute, New York, NY, USA.
• ⁸ DevelRx Ltd. BioCity, Nottingham, And Department of Pharmacy and Pharmacology University of Bath, Bath, UK.
• ⁹ Department of Health Behavior, School of Public Health, University of Alabama at Birmingham, USA.
• ¹⁰ Department of Pharmacology and Experimental Therapeutics, Louisiana State University Health Sciences Center, USA.
• ¹¹ Partner, The Drug and Chemical Advisory Group, LLC, Fairfax, VA, USA.
• ¹² Friends Research Institute, Baltimore, MD, USA.
• ¹³ Department of Health & Human Services National Institutes of Health, National Cancer Institute Division of Cancer Treatment & Diagnosis, Washington, DC, USA.